menu search

Intellia's (ntla) hae candidate gets ema's prime designation

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA...

October 16, 2023, 2:17 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

Pharvaris to present at the apaaaci 2023 international conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor a...

October 13, 2023, 6:50 am

Pharvaris to present at the ciic fall 2023 conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...

October 4, 2023, 7:34 am

Pharvaris to participate in the 2023 cantor global healthcare conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 19, 2023, 6:50 am

Biocryst pharmaceuticals rallies on quebec reimbursement for orladeyo angioedema treatment

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé...

September 18, 2023, 10:53 am

Pharvaris to present at the 18th german allergy congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 6, 2023, 6:51 am

Pharvaris to participate in the morgan stanley 21st annual global healthcare conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 6, 2023, 6:50 am

Astria (atxs) rises 5% on fast track tag for angioedema drug

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to t...

July 21, 2023, 9:12 am

Biocryst selects er-kim pharmaceuticals as commercial partner for orladeyo® (berotralstat) in turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...

July 19, 2023, 11:00 am

Kalvista (kalv) surges 15% on update from angioedema study

KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary ...

July 10, 2023, 11:00 am

Why shares of pharvaris n.v. are up tuesday

Pharvaris has only one drug, deucrictibant, in its pipeline. Deucrictibant is being examined to treat hereditary ...

June 27, 2023, 12:11 pm

Intellia (ntla) up on positive data updates from hae study

Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary ...

June 12, 2023, 11:43 am

Why is intellia (ntla) stock up 5% today?

Intellia (NASDAQ: NTLA ) is trending on social media, and NTLA stock is up over 5% today after the drugmaker reported new, positive results from one o...

June 12, 2023, 10:07 am

Intellia therapeutics announces new positive clinical data from phase 1 study of ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioedema (hae)

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary ...

June 11, 2023, 12:30 pm

Intellia therapeutics to present updated interim data from ongoing phase 1/2 study of ntla-2002 for the treatment of hereditary angioedema (hae) at the eaaci hybrid congress 2023

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the st...

May 31, 2023, 11:30 am

Biocryst to present new orladeyo® (berotralstat) data at 2023 european academy of allergy and clinical immunology congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will prese...

May 31, 2023, 7:02 am

Astria therapeutics to present star-0215 at the 13th c1-inhibitor deficiency and angioedema workshop

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary ...

April 28, 2023, 8:00 am

Kalvista pharmaceuticals to present data at the 13th c1-inhibitor deficiency & angioedema workshop

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa...

April 27, 2023, 6:30 am


Search within

Pages Search Results: